Novel Nanobody Shows Promise in Myasthenia Gravis

19 Oct 2026 0 comments

Exploratory phase 3 data suggest that gefurulimab may reduce the need for rescue therapy and hospitalizations in patients with generalized myasthenia gravis.
Medscape Medical News

Source: Medscape Neurology Published 19 Oct 2026 Imported 19 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment